Intelligent BIO Solutions Inc. $INBS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- New York, NY
- Fiscal year end
- June 30
- Shares outstanding
- 3,027,470 [10-K 2026-08-19]
What the company doesAI summary of filing
Intelligent Bio Solutions Inc. is a medical technology company that develops and commercializes rapid, non-invasive drug screening and diagnostic testing solutions. The company's primary product is the Intelligent Fingerprinting Drug Screening System, a portable point-of-care device that analyzes fingerprint sweat samples using a single-use cartridge and handheld reader to detect drugs of abuse including opiates, cocaine, methamphetamine, benzodiazepines, cannabis, methadone, and buprenorphine. The system is commercially available in select markets outside the United States, primarily the United Kingdom, Europe, Australia, and other regions, with customers including organizations in safety-critical industries, drug treatment centers, and judicial organizations. The company generates revenue from sales of cartridges and readers to over 502 customers, primarily small to medium-sized businesses, and is pursuing FDA 510(k) clearance for the U.S. market while expanding distribution networks internationally. [10-K 2026-08-19]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| FY ended Jun 2026 | $4.22M | −$12.43M | −$11.93M | $3.99M | [10-K 2026-08-19] |
| FY ended Jun 2025 | $3.05M | −$10.57M | −$9.68M | $1.02M | [10-K 2026-08-19] |
- Quarterly cash burn
- −$2.98M
- Cash runway Estimate
- ~4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-04 | 4,386,816 | [10-Q 2024-11-07] |
| 2025-02-11 | 5,278,837 | [10-Q 2025-02-13] |
| 2025-05-09 | 6,910,279 | [10-Q 2025-05-13] |
| 2025-08-12 | 8,979,152 | [10-K 2025-08-15] |
| 2025-11-10 | 9,452,553 | [10-Q 2025-11-12] |
| 2026-02-12 | 1,603,783 | [10-Q 2026-02-12] |
| 2026-05-12 | 2,391,846 | [10-Q 2026-05-13] |
| 2026-08-18 | 3,027,470 | [10-K 2026-08-19] |
- Shelf registration
- S-3 filed 2026-09-15; declared effective 2026-09-23 [S-3 2026-09-15]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-12-16. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-12-16 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-12-16] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-03-18 | Boyages Steven Constantine | grant | 5,000 | — | [4 2026-03-20] |
| 2026-03-18 | Fraser Nicola Marion | grant | 5,000 | — | [4 2026-03-20] |
| 2026-03-18 | Sakiris Spiro Kevin | grant | 9,150 | — | [4 2026-03-20] |
| 2026-03-18 | Sakiris Spiro Kevin | grant | 21,350 | — | [4 2026-03-20] |
| 2026-03-18 | Hurd Jonathan Scott | grant | 5,000 | — | [4 2026-03-20] |
| 2026-03-18 | Isenberg Jason | grant | 5,000 | — | [4 2026-03-20] |
| 2026-03-18 | Simeonidis Harry | grant | 9,150 | — | [4 2026-03-20] |
| 2026-03-18 | Simeonidis Harry | grant | 21,350 | — | [4 2026-03-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-23 | 424B3 | Prospectus or prospectus supplement |
| 2026-09-15 | S-3 | Registration statement |
| 2026-09-11 | 8-K | Other events |
| 2026-09-09 | 8-K | Regulation FD disclosure; Other events |
| 2026-09-02 | 8-K | Material agreement entered; Unregistered sale of equity; Regulation FD disclosure |
| 2026-09-01 | 8-K | Regulation FD disclosure |
| 2026-08-28 | 8-K | Regulation FD disclosure |
| 2026-08-19 | 8-K | Results of operations |
| 2026-08-19 | 10-K | Annual report |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-11 | 8-K | Regulation FD disclosure |
| 2026-08-05 | 8-K | Regulation FD disclosure |
Alerts for $INBS
Email me when Intelligent BIO Solutions Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.